An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
This study uses data from IQVIA’s National Prescription Audit to assess the association of the Inflation Reduction Act’s cap on cost sharing with insulin fills by Medicare beneficiaries.
Conflict of Interest Disclosures: Dr Qato reported being a paid consultant to Public Citizen’s Health Research Group. Dr Goldman reported receiving grants from Amgen, Blue Cross Blue Shield of Arizona, Bristol Myers Squibb, Cedars-Sinai Health System, Edwards Lifesciences, Gates Ventures, Genentech, Gilead Sciences, Johnson & Johnson, KFF (formerly the Kaiser Family Foundation), Novartis, Pfizer, Roche, and Walgreens Boots Alliance; receiving personal fees from the National Railway Labor Conference and Biogen; and being co-founder of EntityRisk and receiving equity for this role. No other disclosures were reported.
Figures
Figure.. Insulin Fills With and Without Medicare…
Figure.. Insulin Fills With and Without Medicare Part D From September 2021 Through April 2023
Figure.. Insulin Fills With and Without Medicare Part D From September 2021 Through April 2023
The data are from IQVIA’s National Prescription Audit on monthly prescription fills for insulin dispensed at retail and mail-order pharmacies in the US. Data from May through August 2022 are omitted to focus on the changes between the end of 1 calendar year and the beginning of the next calendar year.
Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. doi: 10.1001/jama.298.1.61
-
DOI
-
PMC
-
PubMed
Cefalu WT, Dawes DE, Gavlak G, et al. Insulin Access and Affordability Working Group: conclusions and recommendations. Diabetes Care. 2018;41(6):1299-1311. doi: 10.2337/dci18-0019
-
DOI
-
PubMed
McAdam-Marx C, Ruiz-Negron N, Sullivan JM, Tucker JM. The effects of patient out-of-pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014-2018. Health Serv Res. 2023;290(6):1-8. doi: 10.1111/1475-6773.14152
-
DOI
-
PMC
-
PubMed